000162501 001__ 162501
000162501 005__ 20251017144610.0
000162501 0247_ $$2doi$$a10.3390/app15158157
000162501 0248_ $$2sideral$$a145055
000162501 037__ $$aART-2025-145055
000162501 041__ $$aeng
000162501 100__ $$aEsterellas-Sánchez, Laura Karla
000162501 245__ $$aHow Does Left Ventricular Ejection Fraction Affect the Multimodal Assessment of Congestion in Patients with Acute Heart Failure? Results from a Prospective Study
000162501 260__ $$c2025
000162501 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162501 5203_ $$aThe assessment of systemic congestion in acute heart failure (AHF) remains clinically challenging, particularly across different left ventricular ejection fraction (LVEF) phenotypes. This study aimed to evaluate whether differences exist in the degree of congestion, assessed through a multimodal approach including physical examination, biomarkers (NT-proBNP, CA125), and point-of-care ultrasound using the Venous Excess Ultrasound (VExUS) protocol, between patients with preserved (HFpEF) and reduced ejection fraction (HFrEF). We conducted a prospective observational study involving 90 hospitalized AHF patients, 80 of whom underwent a complete VExUS assessment. Although patients with HFrEF exhibited higher levels of NT-proBNP and CA125, and more frequent signs of third-space fluid accumulation such as pleural effusion and ascites, no statistically significant differences were found in VExUS grades between the two groups. These findings suggest that the VExUS protocol provides consistent and reproducible information on systemic venous congestion, regardless of LVEF phenotype. Its integration into clinical practice may help refine congestion assessment and optimize diuretic therapy. Further multicenter studies with larger populations are warranted to validate its diagnostic and prognostic utility and to determine its potential role in guiding individualized treatment strategies in AHF.
000162501 536__ $$9info:eu-repo/grantAgreement/ES/MCIU/PID2022-139143OA-I00
000162501 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttps://creativecommons.org/licenses/by/4.0/deed.es
000162501 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000162501 700__ $$aCampos-Sáenz de Santamaría, Amelia$$uUniversidad de Zaragoza
000162501 700__ $$aAlbines Fiestas, Zoila Stany$$uUniversidad de Zaragoza
000162501 700__ $$aCrespo-Aznarez, Silvia
000162501 700__ $$0(orcid)0000-0002-2338-7637$$aSánchez-Marteles, Marta$$uUniversidad de Zaragoza
000162501 700__ $$aGarcés-Horna, Vanesa$$uUniversidad de Zaragoza
000162501 700__ $$0(orcid)0000-0002-0166-2837$$aAlcaine-Otín, Alejandro
000162501 700__ $$0(orcid)0000-0002-6043-4869$$aGimenez-Lopez, Ignacio$$uUniversidad de Zaragoza
000162501 700__ $$0(orcid)0000-0002-4769-7154$$aRubio-Gracia, Jorge$$uUniversidad de Zaragoza
000162501 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000162501 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000162501 773__ $$g15, 15 (2025), 8157 [12 pp.]$$pAppl. sci.$$tApplied Sciences (Switzerland)$$x2076-3417
000162501 8564_ $$s788452$$uhttps://zaguan.unizar.es/record/162501/files/texto_completo.pdf$$yVersión publicada
000162501 8564_ $$s2653937$$uhttps://zaguan.unizar.es/record/162501/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000162501 909CO $$ooai:zaguan.unizar.es:162501$$particulos$$pdriver
000162501 951__ $$a2025-10-17-14:17:08
000162501 980__ $$aARTICLE